The natural killer (NK) cell activity of the blood and marrow was studied in patients with acute myelogenous leukemia (AML). NKactivity of the cells from blood and marrow was significantly decreased in AMLto three target cell lines. Both binding and killing capacities of the effector cells were deeply depressed in the blood as well as in the marrowat single cell assay. Surface phenotypic analysis showeda significant decrease in CD ll+ cell subsets, but not in CD16+ or Leu-7+ cells, in both blood and marrow cells from AML. A significant decrease of large granular lymphocytes (LGL) was also displayed in these samples at morphological examination. The effector cells from AMLpatients poorly responded to interferon stimulation in NKcytolysis. Taken together, a decrease in CD ll + cell population with LGLmorphology appeared to be responsible for the impaired NKactivity in patients with AML.
Natural killer (NK) cells are a subpopulation of lymphocytes which have cytotoxic activity against a variety of tumor cells (1) . Most NKcells are morphologically defined as large granular lymphocytes (LGL) (2) . However, NKcells are heterogenous cell populations in regard to expression of surface phenotypes (3). Although extensive efforts have been madeto characterize them, the surface antigenic profiles and target cell specificity of heterogenous NK cells have not yet been fully clarified.
Reduced NKactivity has been reported in patients with acute leukemia (4-8). The impaired NKactivity in acute leukemia has been considered to be related to the dilution and replacement of normal lymphocytes with blast cells (7). However, recent investigation has indicated that patients with acute leukemia have primary defects in the cytotoxic capacity of their NK cells, therefore, NK cells could not attack the blasts as targets for NK(8). The observations that patients with pre-leukemic stages have shown reduced NKactivity (9-1 1) and that NKcells restore their cytotoxic activity whencultured in the presence of interleukin-2 (IL-2) (8) are the evidences supporting the above possibility. However, it is still uncertain whether or not specific NKcell populations recognize leukemic blasts. The study in the cloning of LGLfrom human peripheral blood demonstrated that some of the NKcells showeda very limited pattern of specificity and others did multiple recognition patterns to a variety of target cell lines (12). In the above study, the possibility that recognition receptors on the surface of NKcells have been modulated during culture periods for several months could be considered. In the present study, we examined NKactivity of mononuclear cells from blood and marrow in patients with acute leukemia. Both blood and marrow mononuclear cells showed markedly de-pressed cytotoxicity to three target cell lines. The impaired NKactivity was observed in accordance with decreased numbers of CD ll + cells as well as LGL.
The CD1 1 + cell population among heterogenous NKcell populations appeared to be responsible for, at least, decreased NKactivity in acute leukemia.
MATERIALS AND METHODS

Patien ts
Twenty-five patients with acute myelogenous leukemia (AML), 18 males (range: 17-80 years old) and 7 females (range: 32-72 years old) were examined in this study. Diagnosis was based on clinical, morphological, cytochemical and phenotypical findings in each patient. None had received chemotherapyor radiotherapy prior to the sample collection. As the haematological condition was various in AML,the patients were carefully selected on the bases of the percentages of blastic cells in this study. The morphological examination of mononuclear cells (MNC) obtained by F/H isolation from blood and marrow in these patients was in the The optimal ratio of effector to target cells was determined by previous experiments (15). The cytotoxicity assay was run for 6 hours at 37°C in the humidified atmosphere of 5% CO2 incubator. After that, cell mixtures were harvested with trichloroacetic acid in a multiple cell harvester (Labo Science, Tokyo), and the radioactivity of viable cells was counted in a liquid scintillation counter. Cytotoxicity was expressed in a percentage according to the formula shown in the following:
Evaluation of cell morphology Effector cell population was analyzed morphologically by a standard May-Griinwald-Giemsa staining. Differential counts were determined by oil immersion microscopy.
Cell surface immunofluorescence 1 x 105/0.2 ml cells were incubated at 0°C for 30 minutes with appropriated monoclonal antibodies, washed twice and incubated for additional 30 minutes with fluorescein-conjugated goat antimouse immunoglobulin (Cappel, West Chester, PA). After incubation, the cells were washed twice and prepared as wet mounts. The positive cells were counted using a fluorescent microscope.
This assay was performed as described previously (16) . In summary, effector to target conjugates are formed by incubating a 2:1 effector to target mixture of 0.5 ml effector (5 x 105 cells) with 0.5 ml targets (2.5 x 105 cells) in RPMI-1640 medium with 10% FCS in a 10 ml conical tube at 37°C for 15 minutes with subsequent centrifugation (5 minutes at 200 x g). After centrifugation, half of the supernatant was discarded and the pellet was resuspended by gently shaking. Two ml of molted agarose (39°C and not higher) is directly added to this resuspended pellet. The cell-agarose mixture was then quickly spread onto plastic 35-mm dishes (Nunc) which were precoated with poly-L-lysin.
After the agarose had solidifed, 1 ml of MEMwas added to each dish. Dishes were subsequently incubated at 37°C under tissue culture conditions. Six hours later, the plates were removed from the incubator. The mediumwas removed and 1.5 ml of trypan blue was added for 5 minutes, then the dishes were washed with MEM. The lymphocyte to target binding was determined by counting the number of Hospital) at a final concentration of 5,000 U/ml in a 5% CO2 incubator at 37°C. After 2 hours of incubation, the cells were washedwith a mediumand immediately used for testing.
Monoclonal antibodies Anti-human monoclonal antibodies, Leu-7, Leu-1 1 (CD 16) and Leu-M3 were purchased from (Fig. 1) . The marrow cells from the patients with AMLalso showed very low levels of NK activity (4.1 ±2.6% to K-562, 9.0± 3.9% to MOLT-4, 5.5±3.5% to HSB-2) (Fig. 1 ).
This data indicated that NKactivity in patients with AMLwas remarkably depressed in the blood as well as in the marrow (marrow NKactivity in the nor- (Fig. 2) , but that in the marrow did not significantly decrease (4.4±2.4% in AMLto 7.0±2.5% in control) (Fig. 3) .
LGLis not unique to NKcells as activated T cells are morphologically identical to LGL (3). Therefore, the decrease in LGL may reflect the reduced number of activated T cells. The blood and marrowmononuclearcells were then examined on the proportion of the cells expressing NKcell phenotypes using CD ll, CD 16 and Leu-7 mono- clonal antibodies in addition to Leu-M 3 monoclonal antibody (macrophage/monocyte specific). Blood mononuclear cells of AML patients showed an extreme decrease in CD ll+ cells (15.0±2.9% in AMLto 24.2 ± 2.9% in control) (Fig. 2) , while they did not in CD 16+ or Leu-7+ cells (Fig. 2) . The marrow cells from AMLalso showed markedly low levels of CD ll+ cells and Leu-7+ cell to a lesser degree (17.3 ±3.2% in AML to 43.3 ±4.4% in control for CD ll+ cells; 3.2±0.8% in AML to 7.0±2.4% in control for Leu-7+ cells) (Fig. 3) .
The above results demonstrated that a marked decrease in CDll + cells and LGL existed in both blood and marrow cells from AML.This result suggested that a decrease in CD ll + cell subset with
LGLmorphology appeared to be responsible for impaired NKactivity in AML,though there are no direct evidence that decreased CD ll+ cells possessed
LGLmorphology. (Fig. 4) . When the marrow MNCwas treated with IFN, there was no increase in NKactivity in AMLas well as normal subjects (4.4% to 5.7% against K-562, 3.2% to 5.3% against MOLT-4 in AML; 13.4% to 16.3% against K-562, 13.9% to 9.7% against in normal subjects) (Fig. 4) Previous investigators reported the impairment of NKactivity in patients with acute leukemia (4-8).
Some investigators reported that depressed NK activity appeared to be based on the reduced number of effector cells (7) and others did that it was due to a defective killing activity in NKcells (5-8). The evidences that a low NKactivity has been observed in remission stages of the patients with acute lymphoblastic leukemia (6) or preleukemic stages of leukemia patients (9) seem to be a clue to answer this question.
However, it is still unknownwhether specific NK cells for blastic cell killing exist in acute leukemia. LGLmay be powerful NKcapacity among heterogenous NK cell populations. Studies of cytotoxic activity in marrow cells have been very few. Lotzova (8) described that there was a scarcity of NKcells in bone marrow in patients with acute leukemia. Milleck et al. (4) reported that highly depressed NK activity of blood and marrow cells was observed in both the untreated and remission stages of patients with acute leukemia. As the true features of effector cells in charge of NK cytolysis has been uncertain in marrowelements, it is unknownwhether low NKcytotoxicity and insensitivity to IFN is due to immaturity of the precursor NKcells, or whether distinct lineage of cell types attribute to this cytotoxic event.
In conclusion, this study suggested that CD1 1 + cell with LGLsubset among heterogenous NKcell populations plays an important role in NKcytolysis in AML
